Expert Review of Anticancer Therapy最新文献_第2页

Efficacy and safety of fruquintinib combined with PD-1 inhibitors in the treatment of refractory metastatic colorectal cancer: a systematic review and meta-analysis.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-06 DOI: 10.1080/14737140.2025.2474736

Linfeng Liu, Dengzhuo Chen, Liang Wen, Yongli Ma, Jinghui Li, Guosheng Zhang, Hongkai Hu, Chengzhi Huang, Xueqing Yao

{"title":"Efficacy and safety of fruquintinib combined with PD-1 inhibitors in the treatment of refractory metastatic colorectal cancer: a systematic review and meta-analysis.","authors":"Linfeng Liu, Dengzhuo Chen, Liang Wen, Yongli Ma, Jinghui Li, Guosheng Zhang, Hongkai Hu, Chengzhi Huang, Xueqing Yao","doi":"10.1080/14737140.2025.2474736","DOIUrl":"10.1080/14737140.2025.2474736","url":null,"abstract":"Background: Fruquintinib, a VEGFR1-3 tyrosine kinase inhibitor, is approved for treating refractory metastatic colorectal cancer. Recent clinical practice has shown that combining fruquintinib with programmed cell death protein 1 (PD-1) inhibitors can achieve better efficacy.The objective of this study is to assess the efficacy and safety of combining PD-1inhibitors with fruquintinib.Methods: We systematically searched PubMed, Cochrane Library, Embase, Wanfang, and CNKI up to 28 August 2024 for studies comparing fruquintinib combined with PD-1 inhibitors to fruquintinib alone. RevMan software was used to perform meta-analyses of survival data for the included studies.Results: A total of 9 retrospective cohort studies and 1 randomized controlled trial were included, involving a total of 716 patients. Compared with the monotherapy group, the combination therapy group had a greater Overall Response Rate [RR = 2.45,95% CI (1.83, 3.56), p < 0.00001], Disease Control Rate [RR = 1.37,95% CI (1.64,4.79), p = 0.0002], and progression-free survival [HR = 0.64,95% CI (0.49, 0.84), p = 0.001]. However, there was no significant difference in overall survival between the two groups. The incidence of adverse effects was identical in both groups.Conclusion: Fruquintinib combined with PD-1 inhibitors was more effective than fruquintinib alone in the treatment of advanced colorectal cancer, with acceptable safety.Registration: PROSPERO (registration number CRD42024583116).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"411-421"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Overcoming common emerging barriers to effective neoadjuvant immunotherapies.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-03 DOI: 10.1080/14737140.2025.2474733

Sophia Sokol, Marijo Bilusic

{"title":"Overcoming common emerging barriers to effective neoadjuvant immunotherapies.","authors":"Sophia Sokol, Marijo Bilusic","doi":"10.1080/14737140.2025.2474733","DOIUrl":"10.1080/14737140.2025.2474733","url":null,"abstract":"Introduction: Neoadjuvant immunotherapy has rapidly evolved as a novel approach in oncology, reshaping the standard treatment for several malignancies, including melanoma, lung, bladder, colorectal, and breast cancer. While it has an acceptable safety profile, challenges persist due to the complexity of the tumor microenvironment (TME), immune evasion, T-cell exhaustion, and identification of biomarkers. Addressing these issues is critical for optimizing treatment regimens, minimizing immune-related adverse events, and ensuring successful clinical integration.Areas covered: This review explores current research on neoadjuvant immunotherapy, emphasizing its impact on standard of care treatment, efficacy, safety, and clinical challenges. A literature search was conducted using PubMed and ClinicalTrials.gov for studies published in the last 5 years. Ongoing research aims to enhance the efficacy of neoadjuvant immunotherapy, identify resistance mechanisms, and broaden indications. Current clinical trials focus on biomarker-driven patient selection, refining immune response modulation through combination strategies, and developing evidence-based protocols for implementation into routine oncology practice.Expert opinion: Neoadjuvant immunotherapeutic options have rapidly changed the oncological treatment landscape in only a few years, and this treatment paradigm has quickly become a new standard of care in multiple solid tumors. With continued clinical investigation, neoadjuvant immunotherapy has the dramatic potential to further advance cancer care.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"393-403"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-12 DOI: 10.1080/14737140.2025.2468765

Vinay K Giri, Jacob Zaemes

{"title":"The selection of targeted therapies for relapsed or refractory advanced renal cell carcinoma.","authors":"Vinay K Giri, Jacob Zaemes","doi":"10.1080/14737140.2025.2468765","DOIUrl":"10.1080/14737140.2025.2468765","url":null,"abstract":"Introduction: Advancements in immunotherapy and angiogenesis-targeted therapies have transformed the upfront treatment of renal cell carcinoma (RCC). However, long-term prognoses for patients with unresectable and metastatic disease often remain limited, with the majority experiencing progression after exposure to front-line therapy. In most cases of relapsed or refractory (R/R) disease after prior exposure to an immune checkpoint inhibitor (ICI), there is no role for ICI-rechallenge. Therefore, treatment of R/R RCC relies on the appropriate selection of therapies targeting growth pathways dependent on vascular endothelial growth factor (VEGF) or hypoxia-inducible factor (HIF).Areas covered: This review article summarizes the current landscape of targeted therapies for use in second-line or later-line settings for the treatment of clear cell and non-clear cell RCC. Novel therapeutic strategies currently in development are also discussed.Expert opinion: The treatment of R/R RCC primarily consists of inhibition of VEGF, HIF, and mTOR pathways, and the selection of a specific agent depends on the histologic subtype of the tumor, the prior lines of therapy chosen, and patient co-morbidities. Future tumor-based and circulating biomarker research might one day enable the identification of transcriptional signatures that could predict a response to immune, angiogenesis, or HIF-based therapies.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"337-349"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-05 DOI: 10.1080/14737140.2025.2469755

Katarzyna Kisielewska, Piotr Rutkowski

{"title":"An evaluation of vimseltinib for treatment of tenosynovial giant cell tumors.","authors":"Katarzyna Kisielewska, Piotr Rutkowski","doi":"10.1080/14737140.2025.2469755","DOIUrl":"10.1080/14737140.2025.2469755","url":null,"abstract":"Introduction: Tenosynovial giant cell tumor (TGCT) is a rare soft tissue neoplasm with aggressive local growth. The disease is driven by excessive CSF1 expression in tumor cells, leading to increased recruitment of monocytes and macrophages, cytokine production, and tumor development. Targeted therapy against CSF1R is an effective treatment approach for unresectable, symptomatic TGCT. Vimseltinib, a novel, small-molecule tyrosine kinase inhibitor of CSF1R, has shown clinical efficacy in patients with TGCT.Areas covered: This paper outlines the pathogenesis and therapeutic options for TGCT, along with a detailed profile of vimseltinib, including its mechanism of action, pharmacokinetics, efficacy and safety data from clinical studies. The efficacy and tolerability of vimseltinib are indirectly compared with previously known CSF1R inhibitors.Expert opinion: In the MOTION study, the use of vimseltinib in patients with advanced TGCT resulted in a high objective response rate, substantial benefit in reducing clinical symptoms (such as pain and stiffness), and a favorable safety profile. Vimseltinib represents a promising new therapeutic option for patients with unresectable TGCT and is currently awaiting regulatory review by the FDA and EMA.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"327-335"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143522835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic virotherapy - a promising approach in cancer treatment.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-03 DOI: 10.1080/14737140.2025.2474732

Rohit Sharma, Debayan Sil, Dinesh Kumar, Kumari Komal, Sourabh Kumar, Rashmi Ghosh, Vipin Saini, Manish Kumar

引用次数: 0

Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-03-06 DOI: 10.1080/14737140.2025.2474728

Soumaiah Abou Staiteieh, Nouria Faddoul, Berthe Hayar, Bilal Houshaymi, Nadine Darwiche, Raghida Abou Merhi

{"title":"Primary effusion lymphoma: therapeutic strategies targeting viral and cellular mechanisms.","authors":"Soumaiah Abou Staiteieh, Nouria Faddoul, Berthe Hayar, Bilal Houshaymi, Nadine Darwiche, Raghida Abou Merhi","doi":"10.1080/14737140.2025.2474728","DOIUrl":"10.1080/14737140.2025.2474728","url":null,"abstract":"Introduction: Primary effusion lymphoma (PEL) is a rare subtype of B-cell lymphoma primarily affecting immunocompromised and elderly individuals. Given the dismal survival rates associated with traditional treatments, studying novel therapeutic approaches to improve patient outcomes is critical.Areas covered: This review focuses on developing therapeutic options for PEL that target particular viral and cellular mechanisms involved in PEL pathogenesis. Since the CHOP regimen was associated with a lower median survival rate, alternative treatments, including stem cell transplantation, have also been explored, but have generally produced unsatisfactory results. Therefore, novel therapeutic agents are under investigation, including antiretroviral drugs targeting viral pathways and treatments targeting particular cellular processes, such as DNA damage, epigenetics, apoptotic, and immune-modulatory pathways showing promising outcomes in preclinical and clinical research, increasing PEL treatment efficacy while minimizing toxicity. In this review, we conducted a comprehensive literature search using PubMed, and Google Scholar for studies published between 1989 and 2024.Expert opinion: Further research is needed to refine the appropriate combination methods and strategies behind drug interactions. Targeted therapies could be investigated further to improve therapeutic efficacy and reduce toxicity in this type of lymphoma.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"363-381"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

From supportive care to adjunctive treatment: the evolution in time of physical exercise and nutrition in lung cancer.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-02-20 DOI: 10.1080/14737140.2025.2470385

Alice Avancini, Ilaria Trestini, Lorenzo Belluomini, Michele Milella, Sara Pilotto

引用次数: 0

Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-04-01 Epub Date: 2025-02-25 DOI: 10.1080/14737140.2025.2471010

Onur Baş, Mert Tokatlı, Mehmet Şavklıyıldız, Yiğit Yazarkan, Naciye Guduk, Can Kılınç, Latif Karahan, Taha Koray Şahin, Deniz Can Guven, Sercan Aksoy

{"title":"Modified cachexia index and survival in metastatic breast cancer patients treated with CDK 4-6 inhibitors.","authors":"Onur Baş, Mert Tokatlı, Mehmet Şavklıyıldız, Yiğit Yazarkan, Naciye Guduk, Can Kılınç, Latif Karahan, Taha Koray Şahin, Deniz Can Guven, Sercan Aksoy","doi":"10.1080/14737140.2025.2471010","DOIUrl":"10.1080/14737140.2025.2471010","url":null,"abstract":"Background: The objective of this study is to evaluate the correlation between survival outcomes and the modified cachexia index (mCXI) in patients with metastatic breast cancer who have been treated with cyclin-dependent kinase (CDK) 4/6 inhibitors.Methods: This study was conducted on patients with metastatic breast cancer who received CDK 4/6 inhibitors (either Palbociclib or Ribociclib) between January 2020 and November 2024.Results: 240 patients were included. A total of 236 patients (98.3%) were female. Median age was 57 (IQR: 48-66 years). The median follow-up period from the initiation of CDK 4/6 inhibitors to the last control was 20 months. One hundred eighty-four patients (76.7%) received ribociclib, while 56 (23.3%) received palbociclib. At diagnosis, 179 patients (74.6%) had metastatic disease. Patients are classified as modified cachexia index-low (mCXI-Low) and mCXI-High according to the receiver operating characteristic (ROC) analysis results for overall survival (OS) prediction [AUC: 0,654 p:<0,001 Cut-off value = 93.5]. Following multivariate analysis, both progression-free survival [HR: 1.50 (95% CI 1.07-2.12), p = 0.02] and overall survival [HR: 3.22 (95% CI 1.90-5.46), p < 0.001] were found to be significantly associated with mCXI.Conclusion: mCXI is associated with overall survival in metastatic breast cancer patients who are treated with CDK 4-6 inhibitors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"405-409"},"PeriodicalIF":2.9,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Imetelstat in myeloid malignancies: current data and future directions. Imetelstat 在骨髓恶性肿瘤中的应用：当前数据和未来方向。

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-03-28 DOI: 10.1080/14737140.2025.2482721

Aram Bidikian, Jan P Bewersdorf, Tariq Kewan, Nikolai A Podoltsev, Maximilian Stahl, Amer M Zeidan

{"title":"Imetelstat in myeloid malignancies: current data and future directions.","authors":"Aram Bidikian, Jan P Bewersdorf, Tariq Kewan, Nikolai A Podoltsev, Maximilian Stahl, Amer M Zeidan","doi":"10.1080/14737140.2025.2482721","DOIUrl":"10.1080/14737140.2025.2482721","url":null,"abstract":"Introduction: Telomerase reactivation allows cancer cells to maintain telomere length and evade senescence, making it an appealing therapeutic target. Imetelstat, an antisense oligonucleotide, is the first clinically effective telomerase inhibitor approved by the FDA and the European Commission for treating anemia in transfusion-dependent low-risk myelodysplastic syndromes (MDS).Areas covered: Sources for this review were identified through searches of PubMed, ClinicalTrials.gov, and conference abstracts. This review highlights the pharmacology, efficacy, and ongoing trials of imetelstat in treating MDS, myelofibrosis, essential thrombocythemia, and other malignancies. In the IMerge trial, imetelstat induced durable transfusion independence in heavily transfused LR-MDS patients. Pilot trials in myelofibrosis suggest imetelstat's potential disease-modifying properties and survival benefit, warranting further studies of imetelstat as a monotherapy or in combination therapies. Imetelstat can cause thrombocytopenia, leukopenia, elevated liver enzymes, and infusion reactions, which are mostly reversible but may rarely lead to fatal events.Expert opinion: Future clinical trials in LR-MDS should focus on optimal sequencing and combination strategies for imetelstat with other agents, and identifying biomarkers that can predict response. Monitoring real-world outcomes will offer valuable insights into imetelstat's safety and efficacy in patient populations underrepresented in clinical trials. Imetelstat's role in other malignancies, especially myelofibrosis, is being explored.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-12"},"PeriodicalIF":2.9,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment.

IF 2.9 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-03-27 DOI: 10.1080/14737140.2025.2483855

Abdulrahman Alhajahjeh, Maximilian Stahl, Tae K Kim, Tariq Kewan, Jessica M Stempel, Amer M Zeidan, Jan Philipp Bewersdorf

{"title":"Contemporary understanding of myeloid-derived suppressor cells in the acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) tumor microenvironment.","authors":"Abdulrahman Alhajahjeh, Maximilian Stahl, Tae K Kim, Tariq Kewan, Jessica M Stempel, Amer M Zeidan, Jan Philipp Bewersdorf","doi":"10.1080/14737140.2025.2483855","DOIUrl":"10.1080/14737140.2025.2483855","url":null,"abstract":"Introduction: Myeloid-derived suppressor cells (MDSCs) are a key immunosuppressive component in the tumor microenvironment, contributing to immune evasion and disease progression in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).Areas covered: We searched PubMed for literature that evaluated the effect of MDSCs in myeloid diseases. MDSCs impact outcomes by facilitating leukemic stem cell survival, impairing immune checkpoint efficacy, and modulating the bone marrow niche. While these immunosuppressive properties can mitigate graft-versus-host disease post-transplantation, sustained MDSC-mediated immunosuppression can also increase the risk of leukemia relapse.We review MDSC development and function, including metabolic reprogramming, epigenetic modifications, and cytokine-mediated pathways. Therapeutic strategies targeting MDSCs, such as depletion, functional reprogramming, and inhibition of key metabolic and immune pathways, show promising data in preclinical models. However, clinical translation remains hindered by challenges in MDSC quantification and standardization of functional assays. This review underscores the potential of combining MDSC-targeted therapies with conventional and novel treatments to improve patient outcomes in AML and MDS.Expert opinion: Future studies should focus on standardizing MDSC assessment, elucidate their dynamic roles in therapy, and optimize combination approaches for clinical application.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-22"},"PeriodicalIF":2.9,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0